Market Survey on Exophthalmos Treatment Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Exophthalmos Treatment Market including Non-surgical Treatment,and Surgical Treatment Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Exophthalmos Treatment Market Snapshot (2023 to 2033)
The global Exophthalmos Treatment Market is expected to be worth US$ 271.8 Million in the fiscal year 2023, which rose up from US$ 251.2 Million in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 8.2% CAGR, reaching a value of US$ 598 Million by the end of 2033.
Exophthalmos is the term used to describe a condition in which the eyeball bulges outward from the eye socket. Both eyes may be affected or just one. Exophthalmos can result in eye issues such as corneal dryness as well as conjunctivitis, an infection of the interior membrane lining of the eye, depending on how bad it is. In the long run, symptoms usually get better, although it may take years. If therapy is not obtained, it's possible that the eyes will continue to bulge.
Exophthalmos is most often caused by Graves' disease. Around 25 to 50 percent of those who have this illness will also have ocular involvement. It's interesting to note that ocular involvement might happen up to 20 years after a thyroid disorder diagnosis as well as up to 10 years before. Such diseases have been a major driver for exophthalmos treatment from 2023 to 2033.
Along with these causes of the disease, increased research, and development to invent novel drugs for the treatment of exophthalmos disease have been accelerating revenues in the market. The various key players are aimed at developing enhanced medicines and cures, which is also opening up new opportunities for various companies in the global exophthalmos market.
Attributes
Details
Anticipated Base Year Value (2022)
US$ 251.2 Million
Expected Market Value (2023)
US$ 271.8 Million
Projected Forecast Value (2033)
US$ 598 Million
Global Growth Rate (2023 to 2033)
8.2%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Exophthalmos Treatment Market Demand Analysis Vs. Forecast 2023 to 2033
The global Exophthalmos Treatment Market grew at a CAGR of 6.4% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
This market is expanding since occurrences of hyperthyroidism and its comorbidities are becoming more common. In addition to the thyroid, exophthalmos can also be brought on by other reasons, such as internal bleeding from an injury in the eye socket.
The introduction of new administration methods that increase therapeutic effectiveness may accelerate market expansion. The industry is growing because researchers are receiving significant financial assistance for creating innovative interventions. As a result, the global Exophthalmos Treatment Market is expected to forecast a CAGR of over 8% from 2023 to 2033.
Rising cases of hyperthyroidism are triggering the market expansion
Exophthalmos is mostly brought on by Graves' ophthalmopathy, sometimes referred to as thyroid eye illness. One in three patients with an overactive thyroid is affected by this condition. Smokers as well as middle-aged women are the most likely to experience it.
Around 200 million individuals worldwide suffer from thyroid disorders, primarily hyperthyroidism; in the majority of these nations, 50% of the population goes misdiagnosed. The elderly and women are more likely to suffer from this illness. According to data from the Thyroid Foundation of Canada from 2021, congenital hypothyroidism affects 1 across every 1600 children in Canada. As a result, the market has additional opportunities.
Additionally, a shortage of skilled experts with an understanding of thyroid disease treatment options might support the expansion of the global exophthalmos market over the next few years.
Novel treatment and medicine options to accelerate the growth
It is also anticipated that the introduction of innovative methods of administration that improve the medications' efficacy would restrain the market's expansion for exophthalmos therapy. Additionally, in the upcoming years, there may be more prospects for the expansion of the exophthalmos therapy market due to advancements in antibiotics, nutrition, and innovative treatments.
For instance, Tepezza was authorized by the US Food and Drug Administration (FDA) in 2020 for the treatment of people with exophthalmos. It was the first medication to be authorized for the treatment of exophthalmos. Tepezza has been designated as an orphan medicine, which offers incentives to help and promote the development of medications for uncommon illnesses or ailments. The FDA Orphan Medicines Money Program, which offers grants for clinical investigations on the safety and efficacy of products for use in uncommon illnesses or disorders, also contributed to the development of this medication. As a result, it is anticipated that further research and development will be opening up new avenues for the market players during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
What Could Possibly Hinder Exophthalmos Treatment Market Demand?
Increasing government initiatives and awareness programs impede the global market
As hyperthyroidism is considered to be the primary cause of exophthalmos disease, various governments across nations have been working towards cutting down the incidence of thyroid cases globally. In such a case, with lowering thyroid cases, the cases for exophthalmos will go down as well, hence restraining the market growth during the forecast period.
Collaboration agreements between public and commercial entities have increased, which helps to educate healthcare professionals about thyroid treatment. The American Academy of Otolaryngology, British Thyroid Foundation, American Thyroid Association (ATA), and Thyroid Foundation of Canada are just a few of the government groups that are actively raising awareness of the condition and its available treatments. These kinds of steps are expected to hinder market expansion from 2023 to 2033.
Region-wise Analysis
What is the outlook of the North American Exophthalmos Treatment Market?
Rising incidence of thyroid cases along with novel drugs development will boost the growth
During the forecast period, the North American market for exophthalmos disease is expected to be the most volatile one. As per Future Market Insights, this region is expected to prolifer with a robust CAGR of 8.7% from 2023 to 2033.
North America is anticipated to lead the market due to important factors such as the rising incidence of different thyroid illnesses in the USA as well as the development of novel treatment options. Around 18 in 100,000 Americans have exophthalmos disease, as per data from the American Academy of Ophthalmology that was released in July 2022. As a result, the expansion of the market under investigation in the area will be aided by the exophthalmos disease's prevalence in the USA.
The market for exophthalmos illness is expanding as a result of notable product releases, a high proportion of market participants, and the presence of companies in the US. For example, in January 2020, Horizon Therapeutics PLC reported that the Food and Drug Administration approved TEPEZZA to treat exophthalmos disease. Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 39% in the year 2023.
What can be expected from the Asia Pacific market for Exophthalmos Treatment?
Increasing cases of Grave’s disease along with thyroid cases accelerate the growth
During the forecast period, the Asia Pacific market for Exophthalmos Treatment is expected to garner a steady CAGR of 7.1%.
Countries like China and India were reported to have most of the exophthalmos cases in the Asia Pacific region. For instance, in India, one of the most prevalent endocrine conditions affecting roughly 42 million Indians is thyroid disease. And about 31% of these people eventually start to experience exophthalmos disease symptoms. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which treatment segment is expected to gain traction from 2023 to 2033?
The non-surgical segment will gain the dominant market share
Over the course of the forecast period, the non-surgical segment by treatment type is anticipated to occupy a significant share of the global exophthalmos treatment market. In 2023, this category is anticipated to dominate with a 53% revenue share.
Whenever the patients start experiencing the symptoms of bulging out of the eyes, immediately they reach out to the ophthalmologist, who mostly prescribes certain eye drops and antibiotics. With the advancements in medications, there are now certain eye drops that have steroids as well to immediately bring the eyeball back to normal size. Hence, in such a scenario, no surgery is required. Such factors are expected to accelerate the growth prospects for exophthalmos treatment from 2023 to 2033.
Which end-user segment is expected to gain traction from 2023 to 2033?
The specialty clinics segment will demand during the forecast period.
According to the research by Future Market Insights, the specialty clinic segments will gain traction during the forecast period. It is anticipated that this segment will occupy a global market share of 25% from 2023 to 2033.
During a case of exophthalmos, patients prefer visiting an eye clinic, rather than a hospital. These specialty clinics offer patients a wide range of treatment options as well as doctors. At the same time, treatment over here is quite affordable when compared to that of a hospital. Hence, during the forecast period, this segment is expected to acquire more than half of the global exophthalmos market in 2023.
Start-up Scenario
The newly founded businesses in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.
GenSight Biologics is a biotechnology business in the clinical stages of research and development that identifies and creates innovative treatments for neurodegenerative as well as mitochondrial illnesses of the eye and the central nervous system. They utilize their integrated development platform to tackle these therapeutic areas by integrating a gene therapy-based strategy with our primary technological platforms, mitochondrial targeting sequence, and optogenetics.
Leading AI diagnostics business IDx is on a quest to improve the standard, availability, and cost of healthcare. The company's initial offering, IDx-DR, is an automation diagnostic system with FDA clearance for use in the field to identify diabetic retinopathy. For the diagnosis of macular degeneration, exophthalmos, Alzheimer's disease, glaucoma, cardiovascular disease, and stroke risk, IDx is creating more AI-based diagnostic algorithms.
Competitive Landscape
Some of the prominent players in the global market for Exophthalmos Treatment are:
Eyevance Pharmaceuticals
Sling Therapeutics
Competition Deep Dive
AbbVie
Alcon
Avik Pharma
Anuh Pharma Ltd.
Pfizer CentreOne
Pipelinepharma
Mylan N.V.
Manus Aktteva Biopharma LLP
Roche
Some of the prominent developments of the key players in the market are:
In 2019, Eyevance Pharmaceuticals announced that it has purchased Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% as well as Natacyn (natamycin ophthalmic suspension) 5% from Novartis. The purchase of Tobradex ST and Natacyn is the most recent development in Eyevance's expansion plan, which also included the license or purchase of other ophthalmic pharmaceutical goods in 2017 and 2018.
A biopharmaceutical business called Sling Therapeutics, Inc. announced its formal launch in 2022 with a $35 million Series A investment led by TPG's The Rise Fund. The company is focused on late-stage research of an oral small molecule for the treatment of exophthalmos. The money will go toward Phase 2b clinical research examining the effectiveness of linsitinib, an experimental medication from the business, in treating exophthalmos disease.
Scope of Report
Report Attribute
Details
Growth Rate
CAGR of 8.2% from 2023 to 2033
Market value in 2023
US$ 271.8 Million
Market value in 2033
US$ 598 Million
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
USD Million for Value
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Treatment
End-user
Region
Regions Covered
North America
Latin America
Asia Pacific
Europe
Middle East & Africa
Key Countries Profiled
United States of America
Canada
Mexico
Brazil
Germany
Italy
France
United Kingdom
Spain
Poland
Russia
China
India
ASIAN
Australia
New Zealand
Japan
GCC Countries
S. Africa
Northern Africa
Key Companies Profiled
Competition Deep Dive
AbbVie
Alcon
Avik Pharma
Anuh Pharma Ltd.
Pfizer CentreOne
Pipelinepharma
Mylan N.V.
Manus Aktteva Biopharma LLP
Roche
Eyevance Pharmaceuticals
Sling Therapeutics
Customisation Scope
Available on Request
Key Segments Covered In The Exophthalmos Treatment Market Report
Exophthalmos Treatment Market By Treatment:
Non-surgical Treatment
Sympathomimetic Amines
Corticosteroids
Secondary Metabolites
Monoclonal Antibodies
Radiotherapy
Surgical Treatment
Orbital Decompression
Eye Muscle Surgery
Eyelid Surgery
Exophthalmos Treatment Market By End User:
Hospital Pharmacies
Specialty Clinics
Others
Exophthalmos Treatment Market By Region:
North America
Latin America
Asia Pacific
Europe
Middle East & Africa (MEA)
Frequently Asked Questions
How Much the Market is Slated to Attain?
The market is slated to attain US$ 271.8 million in 2023.
At What Speed, the Market is Expected to Expand?
The market is expected to expand at a CAGR of 8.2% through 2033.
Which Factors are Facilitating Market Growth?
Novel treatment and medicine options are catapulting the market growth.
Which Factors are Causing Hinderance for Market Growth?
Increasing steps to lower the emergence of exophthalmos through government programs is expected to cause hinderance for market.
What is North America’s Scope for Growth?
North America is expected to expand at a CAGR of 8.7%.
Table of Content
1. Executive Summary | Exophthalmos Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Non-surgical Treatment
5.3.1.1. Sympathomimetic Amines
5.3.1.2. Corticosteroids
5.3.1.3. Secondary Metabolites
5.3.1.4. Monoclonal Antibodies
5.3.1.5. Radiotherapy
5.3.2. Surgical Treatment
5.3.2.1. Orbital Decompression
5.3.2.2. Eye Muscle Surgery
5.3.2.3. Eyelid Surgery
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States of America
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End Users
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End Users
8.4. Key Takeaways
9. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End Users
9.4. Key Takeaways
10. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End Users
10.4. Key Takeaways
11. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End Users
11.4. Key Takeaways
12. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End Users
12.4. Key Takeaways
13. Key Countries Analysis
13.1. United States of America
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End Users
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End Users
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End Users
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End Users
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End Users
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End Users
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End Users
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End Users
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End Users
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End Users
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End Users
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End Users
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End Users
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End Users
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End Users
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End Users
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End Users
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End Users
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End Users
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End Users
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End Users
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Spectra Vision Care
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. AbbVie
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Alcon
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Avik Pharma
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Anuh Pharma Ltd.
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Pfizer CentreOne
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Pipelinepharma
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Mylan N.V.
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Manus Aktteva Biopharma LLP
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Roche
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region,2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Treatment,2018 to 2033
Table 3: Global Value (US$ Million) Forecast by End Users,2018 to 2033
Table 4: North America Value (US$ Million) Forecast by Country,2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Treatment,2018 to 2033
Table 6: North America Value (US$ Million) Forecast by End Users,2018 to 2033
Table 7: Latin America Value (US$ Million) Forecast by Country,2018 to 2033
Table 8: Latin America Value (US$ Million) Forecast by Treatment,2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by End Users,2018 to 2033
Table 10: Europe Value (US$ Million) Forecast by Country,2018 to 2033
Table 11: Europe Value (US$ Million) Forecast by Treatment,2018 to 2033
Table 12: Europe Value (US$ Million) Forecast by End Users,2018 to 2033
Table 13: Asia Pacific Value (US$ Million) Forecast by Country,2018 to 2033
Table 14: Asia Pacific Value (US$ Million) Forecast by Treatment,2018 to 2033
Table 15: Asia Pacific Value (US$ Million) Forecast by End Users,2018 to 2033
Table 16: MEA Value (US$ Million) Forecast by Country,2018 to 2033
Table 17: MEA Value (US$ Million) Forecast by Treatment,2018 to 2033
Table 18: MEA Value (US$ Million) Forecast by End Users,2018 to 2033
List of Charts
Figure 1: Global Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Value (US$ Million) by End Users, 2023 to 2033
Figure 3: Global Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Value (US$ Million) Analysis by Region,2018 to 2033
Figure 5: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Value (US$ Million) Analysis by Treatment,2018 to 2033
Figure 8: Global Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Value (US$ Million) Analysis by End Users,2018 to 2033
Figure 11: Global Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 12: Global Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 13: Global Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Attractiveness by End Users, 2023 to 2033
Figure 15: Global Attractiveness by Region, 2023 to 2033
Figure 16: North America Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Value (US$ Million) by End Users, 2023 to 2033
Figure 18: North America Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Value (US$ Million) Analysis by Country,2018 to 2033
Figure 20: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Value (US$ Million) Analysis by Treatment,2018 to 2033
Figure 23: North America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by End Users,2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 28: North America Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Attractiveness by End Users, 2023 to 2033
Figure 30: North America Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Value (US$ Million) by End Users, 2023 to 2033
Figure 33: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Value (US$ Million) Analysis by Country,2018 to 2033
Figure 35: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Value (US$ Million) Analysis by Treatment,2018 to 2033
Figure 38: Latin America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Value (US$ Million) Analysis by End Users,2018 to 2033
Figure 41: Latin America Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 42: Latin America Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 43: Latin America Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Attractiveness by End Users, 2023 to 2033
Figure 45: Latin America Attractiveness by Country, 2023 to 2033
Figure 46: Europe Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Value (US$ Million) by End Users, 2023 to 2033
Figure 48: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Value (US$ Million) Analysis by Country,2018 to 2033
Figure 50: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Value (US$ Million) Analysis by Treatment,2018 to 2033
Figure 53: Europe Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Value (US$ Million) Analysis by End Users,2018 to 2033
Figure 56: Europe Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 57: Europe Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 58: Europe Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Attractiveness by End Users, 2023 to 2033
Figure 60: Europe Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Asia Pacific Value (US$ Million) by End Users, 2023 to 2033
Figure 63: Asia Pacific Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Value (US$ Million) Analysis by Country,2018 to 2033
Figure 65: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Value (US$ Million) Analysis by Treatment,2018 to 2033
Figure 68: Asia Pacific Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: Asia Pacific Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: Asia Pacific Value (US$ Million) Analysis by End Users,2018 to 2033
Figure 71: Asia Pacific Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 72: Asia Pacific Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 73: Asia Pacific Attractiveness by Treatment, 2023 to 2033
Figure 74: Asia Pacific Attractiveness by End Users, 2023 to 2033
Figure 75: Asia Pacific Attractiveness by Country, 2023 to 2033
Figure 76: MEA Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: MEA Value (US$ Million) by End Users, 2023 to 2033
Figure 78: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Value (US$ Million) Analysis by Country,2018 to 2033
Figure 80: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Value (US$ Million) Analysis by Treatment,2018 to 2033
Figure 83: MEA Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: MEA Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: MEA Value (US$ Million) Analysis by End Users,2018 to 2033
Figure 86: MEA Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 87: MEA Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 88: MEA Attractiveness by Treatment, 2023 to 2033
Figure 89: MEA Attractiveness by End Users, 2023 to 2033
Figure 90: MEA Attractiveness by Country, 2023 to 2033
